

52. A method of selecting antibodies from an antibody library, comprising screening said antibody library with an antigen, wherein said antibody library consists of phagemids according to either claim 47 or claim 48.

53. A method of presenting a peptide or protein at the surface of a phagemid viral particle, comprising producing said phagemid viral particle, wherein said phagemid viral particle comprises a DNA sequence encoding said peptide or protein fused to a DNA sequence encoding a contiguous full length coliphage pIII protein.

REMARKS

The substitute specification adds no new matter. Support for claim 44 is found throughout the specification which discloses and exemplifies *inter alia* methods for preparation and selection of binding proteins using phagemid display technology in combination with mutagenesis.

The new claims are related to phagemids and their use for creating a fusion protein comprising a specific binding pair member and gene III protein. Support for the claims is found at various places throughout the specification, for example, on page 15, lines 13-30 carrying over to page 16, lines 1-3; page 18, lines 1-22; and page 96, lines 6-14. (Page numbers refer to substitute specification). Claims 44-46 correspond to Group II as defined by the Examiner in a restriction requirement issued December 7, 1998 in the parent application, U.S. Serial No. 08/484,893 filed June 7, 1995. Claims 47-53 correspond to claims 1-7 in U.S. Patent No. 5,849,500.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN

By


Jill E. Uhl, Reg. No. 43,213
Attorneys for Applicants
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

October 13, 1999